NASDAQ:INZY

Inozyme Pharma (INZY) Stock Forecast, Price & News

$6.43

+0.06 (+0.94%)

(As of 06/2/2023 ET)

Compare

Today's Range: $6.31
▼
$6.58
50-Day Range: $3.70
▼
$6.74
52-Week Range: $0.99
▼
$7.24

Volume: 567,612 shs
Average Volume: 1.19 million shs
Market Capitalization: $283.11 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.00

Inozyme Pharma MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 148.8% Upside
$16.00 Price Target
Short Interest: Healthy
1.73% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$3.17 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.70) to ($1.67) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.24 out of 5 stars

Medical Sector

542nd out of 983 stocks

Pharmaceutical Preparations Industry

265th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Inozyme Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.00, Inozyme Pharma has a forecasted upside of 148.8% from its current price of $6.43.
Amount of Analyst Coverage
Inozyme Pharma has only been the subject of 3 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.73% of the float of Inozyme Pharma has been sold short.
Short Interest Ratio / Days to Cover
Inozyme Pharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month

0.0

Dividend Strength

Dividend Yield
Inozyme Pharma does not currently pay a dividend.
Dividend Growth
Inozyme Pharma does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INZY.

2.1

News and Social Media Coverage

News Sentiment
Inozyme Pharma has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Inozyme Pharma this week, compared to 1 article on an average week.
Search Interest
Only 10 people have searched for INZY on MarketBeat in the last 30 days. This is a decrease of -74% compared to the previous 30 days.
MarketBeat Follows
Only 3 people have added Inozyme Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Inozyme Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $3,174,032.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 9.72% of the stock of Inozyme Pharma is held by insiders.
Percentage Held by Institutions
76.35% of the stock of Inozyme Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Inozyme Pharma are expected to grow in the coming year, from ($1.70) to ($1.67) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Inozyme Pharma is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Inozyme Pharma is -4.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Inozyme Pharma has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Inozyme Pharma (NASDAQ:INZY) Stock

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Receive INZY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inozyme Pharma and its competitors with MarketBeat's FREE daily newsletter.

INZY Stock News Headlines

June 2, 2023 | finance.yahoo.com

Inozyme Pharma to Present at the Jefferies Healthcare Conference

May 17, 2023 | americanbankingnews.com

Robert Lorne Hopfner Buys 219,230 Shares of Inozyme Pharma, Inc. (NASDAQ:INZY) Stock

June 3, 2023 | Stocks To Trade (Ad)

Free SMS Trade Alerts. Up to 15 opportunities a day.

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 16, 2023 | benzinga.com

Inozyme Pharma Insider Trades Send a Signal

May 14, 2023 | americanbankingnews.com

Q2 2023 Earnings Forecast for Inozyme Pharma, Inc. Issued By HC Wainwright (NASDAQ:INZY)

May 9, 2023 | finanznachrichten.de

Inozyme Pharma Inc.: Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

May 9, 2023 | msn.com

Recap: Inozyme Pharma Q1 Earnings

May 9, 2023 | finance.yahoo.com

Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights

June 3, 2023 | Legacy Research (Affiliate) (Ad)

Sell Every Stock, Except ONE (Ticker Revealed)

We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.

May 3, 2023 | finance.yahoo.com

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 22, 2023 | americanbankingnews.com

Inozyme Pharma's (INZY) Buy Rating Reaffirmed at Needham & Company LLC

April 19, 2023 | msn.com

Analyst Ratings for Inozyme Pharma

April 19, 2023 | msn.com

Needham Reiterates Inozyme Pharma (INZY) Buy Recommendation

April 16, 2023 | finance.yahoo.com

A number of insiders bought Inozyme Pharma, Inc. (NASDAQ:INZY) stock last year, which is great news for shareholders

April 14, 2023 | finance.yahoo.com

Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)

April 11, 2023 | finance.yahoo.com

Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference

April 7, 2023 | 247wallst.com

Pivotal bioVenture Partners Fund I Now Owns 7.4% of Inozyme Pharma

April 4, 2023 | finance.yahoo.com

Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer

April 2, 2023 | americanbankingnews.com

Insider Buying: Inozyme Pharma, Inc. (NASDAQ:INZY) Director Buys $1,564,447.68 in Stock

March 31, 2023 | americanbankingnews.com

Insider Buying: Inozyme Pharma, Inc. (NASDAQ:INZY) Director Buys 51,074 Shares of Stock

March 29, 2023 | benzinga.com

Inozyme Pharma Inc (INZY) is higher by 32.61% in a Week, Should You Buy?

March 29, 2023 | americanbankingnews.com

Jefferies Financial Group Weighs in on Inozyme Pharma, Inc.'s Q1 2023 Earnings (NASDAQ:INZY)

March 28, 2023 | finance.yahoo.com

Here's Why Inozyme Pharma Has My Attention

March 28, 2023 | americanbankingnews.com

Q1 2023 EPS Estimates for Inozyme Pharma, Inc. (NASDAQ:INZY) Increased by Analyst

March 26, 2023 | americanbankingnews.com

Analysts Offer Predictions for Inozyme Pharma, Inc.'s Q2 2023 Earnings (NASDAQ:INZY)

March 24, 2023 | americanbankingnews.com

Inozyme Pharma (NASDAQ:INZY) Upgraded to "Buy" by Jefferies Financial Group

March 24, 2023 | americanbankingnews.com

Wedbush Reiterates "Outperform" Rating for Inozyme Pharma (NASDAQ:INZY)

See More Headlines

INZY Price History

30 days | 90 days | 365 days | Advanced Chart

INZY Company Calendar

Last Earnings: 3/22/2023
Today: 6/03/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INZY
CUSIP: N/A
CIK: 1693011
Web: www.inozyme.com
Phone: 857-330-4340
Fax: N/A
Employees: 50
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $16.00
High Stock Price Forecast: $23.00
Low Stock Price Forecast: $6.00
Forecasted Upside/Downside: +148.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.58)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-67,060,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -53.46%
Return on Assets: -45.28%

Debt

Debt-to-Equity Ratio: 0.23
Current Ratio: 10.66
Quick Ratio: 10.66

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.35 per share
Price / Book: 2.74

Miscellaneous

Outstanding Shares: 44,030,000
Free Float: 39,755,000
Market Cap: $283.11 million
Optionable: Not Optionable
Beta: 1.08

Key Executives

Mr. Axel Bolte M.B.A. (Age 50)
M.Sc., Co-Founder, Pres, CEO & Director
Comp: $889.66k

Mr. Henric Bjorn Bjarke (Age 55)
Sr. VP & COO
Comp: $597.68k

Dr. Demetrios Braddock M.D.
Ph.D., Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer

Mr. Sanjay S. Subramanian M.B.A. (Age 45)
M.S., CFO & Principal Accounting Officer

Dr. Soojin Kim Ph.D.
Sr. VP & Chief Technical Operations Officer

Dr. Yves Sabbagh Ph.D.
Chairman of Scientific Advisory Board, Sr. VP & Chief Scientific Officer

Mr. Stefan Riley
Director of Investor Relations

Ms. Gayle Gironda
Sr. VP & Chief People Officer

Dr. David Thompson M.A.
M.S., Ph.D., Chief Devel. Officer

Mr. Stephen J. Di Palma M.B.A (Age 63)
M.B.A., Consultant

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INZY Stock - Frequently Asked Questions

Should I buy or sell Inozyme Pharma stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Inozyme Pharma in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INZY shares.
View INZY analyst ratings or view top-rated stocks.
What is Inozyme Pharma's stock price forecast for 2023?: 4 brokerages have issued 1 year price objectives for Inozyme Pharma's shares. Their INZY share price forecasts range from $6.00 to $23.00. On average, they anticipate the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 148.8% from the stock's current price.
View analysts price targets for INZY or view top-rated stocks among Wall Street analysts.
How have INZY shares performed in 2023?: Inozyme Pharma's stock was trading at $1.05 on January 1st, 2023. Since then, INZY shares have increased by 512.4% and is now trading at $6.43.
View the best growth stocks for 2023 here.
When is Inozyme Pharma's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our INZY earnings forecast.
How were Inozyme Pharma's earnings last quarter?: Inozyme Pharma, Inc. (NASDAQ:INZY) posted its quarterly earnings data on Wednesday, March, 22nd. The company reported ($0.42) earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.04.
What other stocks do shareholders of Inozyme Pharma own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Inozyme Pharma investors own include Procter & Gamble (PG), Raytheon Technologies (RTX), Cisco Systems (CSCO), CSX (CSX), CVS Health (CVS), Home Depot (HD), Resideo Technologies (REZI), Thermo Fisher Scientific (TMO) and Abbott Laboratories (ABT).

When did Inozyme Pharma IPO?: (INZY) raised $75 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Cowen and Piper Sandler served as the underwriters for the IPO and Wedbush PacGrow was co-manager.
What is Inozyme Pharma's stock symbol?: Inozyme Pharma trades on the NASDAQ under the ticker symbol "INZY."
Who are Inozyme Pharma's major shareholders?: Inozyme Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Sphera Funds Management LTD. (4.05%), CHI Advisors LLC (3.07%), Affinity Asset Advisors LLC (1.72%), FMR LLC (1.61%), Samsara BioCapital LLC (1.15%) and BlackRock Inc. (1.03%). Insiders that own company stock include Axel Bolte, Henric Bjorn Bjarke, Holdings A/S Novo, Longitude Capital Partners Iii and Robert Lorne Hopfner.
View institutional ownership trends.
How do I buy shares of Inozyme Pharma?: Shares of INZY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Inozyme Pharma's stock price today?: One share of INZY stock can currently be purchased for approximately $6.43.
How much money does Inozyme Pharma make?: Inozyme Pharma (NASDAQ:INZY) has a market capitalization of $283.11 million. The company earns $-67,060,000.00 in net income (profit) each year or ($1.58) on an earnings per share basis.
How can I contact Inozyme Pharma?: The official website for the company is www.inozyme.com. The company can be reached via phone at 857-330-4340 or via email at ir@inozyme.com.

This page (NASDAQ:INZY) was last updated on 6/3/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial